Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.Mohammad Atiq, Ravi A. Madan, Marijo Bilušić et al.|Journal of Clinical Oncology|2022Cited by 4
Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study.Mohammad Atiq, Ravi A. Madan, Elias Bin Aris Chandran et al.|Journal of Clinical Oncology|2022Cited by 3